Detect the Omicron variant of SARS-CoV-2 with Meridian Bioscience's new antibody pair
Meridian Bioscience has developed a novel SARS-CoV-2 nucleocapsid monoclonal antibody pair that detects the conserved SARS-CoV-2 nucleoprotein domain highly specifically and does not cross-react with seasonal coronavirus strains. This pair of antibodies can be used to develop reliable rapid antigen tests. The SARS-CoV-2 nucleocapsid antibody pair consists of a capture and a detection antibody. New data from an FDA-approved lateral flow assay show that this antibody pair detects the Omicron variant (B.1.1.529) down to 1.31 x 102 PFU/mL and all other variants down to 1.88 x 102 PFU/mL in clinical samples. The antibody pair has been validated for use in lateral flow and ELISA assays, has over 95 % purity, and is already used in FDA EUA and CE-marked kits.
Please contact us for more information or visit our website at www.dunnlab.de.
Dr. Stefan Paulusch • Product Manager
Dunn Labortechnik GmbH • Thelenberg 6 • DE-53567 Asbach
Tel. +49 (0) 26 83 / 4 30 94 • Fax +49 (0) 26 83 / 4 27 76